CME
Program Description:
The experimental antibody-drug conjugate trastuzumab emtansine (T-DM1) has shown significant improvement in progression-free survival (PFS) compared with capecitabine plus lapatinib among patients with HER2+ locally advanced or metastatic breast cancer (MBC) previously treated with a taxane and trastuzumab, according to primary results from the randomized phase 3 EMILIA trial reported at the 2012 Annual Meeting of the American Society of Clinical Oncology.
Continue Reading
INTENDED AUDIENCE:
Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with breast cancer.
Activity Objectives:
After participating in this educational activity, participants should be better able to:
- Evaluate the efficacy and safety of the experimental antibody-drug conjugate trastuzumab emtansine (T-DM1) among patients with HER2+ locally advanced or metastatic breast cancer.
- Develop protocols to increase PFS among patients with HER2+ locally advanced or metastatic breast cancer who are inadequately responsive to established treatment protocols.
Click Next to begin the activity.
